Auro Laboratories Past Earnings Performance
Past criteria checks 4/6
Auro Laboratories's earnings have been declining at an average annual rate of -6.9%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 3.5% per year. Auro Laboratories's return on equity is 19.4%, and it has net margins of 13.1%.
Key information
-6.9%
Earnings growth rate
-6.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 3.5% |
| Return on equity | 19.4% |
| Net Margin | 13.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Auro Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 551 | 72 | 44 | 0 |
| 30 Sep 23 | 527 | 48 | 43 | 0 |
| 30 Jun 23 | 519 | 31 | 44 | 0 |
| 31 Mar 23 | 529 | 24 | 47 | 0 |
| 31 Dec 22 | 573 | 11 | 52 | 0 |
| 30 Sep 22 | 538 | 14 | 56 | 0 |
| 30 Jun 22 | 515 | 19 | 60 | 0 |
| 31 Mar 22 | 509 | 28 | 62 | 0 |
| 31 Dec 21 | 465 | 39 | 62 | 0 |
| 30 Sep 21 | 475 | 53 | 62 | 0 |
| 30 Jun 21 | 526 | 69 | 61 | 0 |
| 31 Mar 21 | 543 | 72 | 60 | 0 |
| 31 Dec 20 | 501 | 61 | 61 | 0 |
| 30 Sep 20 | 466 | 51 | 59 | 0 |
| 30 Jun 20 | 423 | 43 | 55 | 0 |
| 31 Mar 20 | 438 | 41 | 53 | 0 |
| 31 Dec 19 | 459 | 52 | 47 | 0 |
| 30 Sep 19 | 486 | 55 | 43 | 0 |
| 30 Jun 19 | 501 | 49 | 42 | 0 |
| 31 Mar 19 | 468 | 44 | 41 | 0 |
| 31 Dec 18 | 466 | 37 | 45 | 0 |
| 30 Sep 18 | 466 | 36 | 42 | 0 |
| 30 Jun 18 | 437 | 37 | 38 | 0 |
| 31 Mar 18 | 408 | 35 | 37 | 0 |
| 31 Dec 17 | 396 | 32 | 32 | 0 |
| 30 Sep 17 | 346 | 20 | 31 | 0 |
| 30 Jun 17 | 330 | 14 | 32 | 0 |
| 31 Mar 17 | 355 | 8 | 31 | 0 |
| 31 Dec 16 | 331 | 15 | 27 | 0 |
| 30 Sep 16 | 344 | 14 | 27 | 0 |
| 30 Jun 16 | 314 | 13 | 26 | 0 |
| 31 Mar 16 | 279 | 9 | 25 | 0 |
| 31 Dec 15 | 288 | 8 | 43 | 0 |
| 30 Sep 15 | 285 | 8 | 43 | 0 |
| 30 Jun 15 | 323 | 8 | 23 | 0 |
| 31 Mar 15 | 326 | 8 | 22 | 0 |
| 31 Dec 14 | 301 | 5 | 33 | 0 |
| 30 Sep 14 | 300 | 5 | 32 | 0 |
| 30 Jun 14 | 304 | 5 | 39 | 0 |
| 31 Mar 14 | 337 | 6 | 34 | 0 |
| 31 Dec 13 | 467 | 7 | 21 | 0 |
| 30 Sep 13 | 417 | 5 | 22 | 0 |
| 30 Jun 13 | 451 | 8 | 21 | 0 |
Quality Earnings: 530233 has high quality earnings.
Growing Profit Margin: 530233's current net profit margins (13.1%) are higher than last year (1.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530233's earnings have declined by 6.9% per year over the past 5 years.
Accelerating Growth: 530233's earnings growth over the past year (545.4%) exceeds its 5-year average (-6.9% per year).
Earnings vs Industry: 530233 earnings growth over the past year (545.4%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 530233's Return on Equity (19.4%) is considered low.